Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Jenny is Head of Preclinical Development at bluebird bio, where she is responsible for the nonclinical development of a broad portfolio of gene and cell therapies from early Research to the market. Jenny began her career at Novartis, Switzerland, where she headed a laboratory focused on molecular mechanisms of carcinogenesis and epigenetic mechanisms of adverse drug effects. She transitioned to Novartis, Cambridge after two years to establish a new Molecular Toxicology group focused on molecular on- and off-target mechanisms of toxicity as well as understanding mechanisms of adverse effects of systemically delivered nucleic acid therapeutics. Jenny held positions of increasing responsibility within the Investigative Toxicology and Preclinical Safety functions at Novartis, directing projects across a broad portfolio of indications and drug modalities. Prior to joining Novartis, Jenny earned a PhD in Molecular Toxicology, with an emphasis in cellular and molecular mechanisms of carcinogenesis, from the Department of Environmental Health Sciences at the University of Cincinnati. She also holds a Bachelor of Science degree in Zoology (Miami University, Oxford, Ohio).